Earnings ·
C4 Therapeutics reports Q3 revenue of $8.5M and net loss of $21.8M
CCCCC4 Therapeutics, Inc.
C4 Therapeutics reported third-quarter 2026 total revenue of $8.5 million, down from $11.2 million in the prior-year period, primarily due to the conclusion of certain research activities with Merck. Research and development expenses decreased to $24.8 million from $26.0 million, while general and administrative expenses fell to $8.3 million from $8.9 million. The company reported a net loss of $21.8 million, or $0.16 per share, compared to a net loss of $32.2 million, or $0.44 per share, in the same quarter last year. Cash, cash equivalents, and marketable securities stood at $274.7 million as of September 30, 2026. The company remains focused on advancing its cemsidomide clinical programs for multiple myeloma.